As CBO at Lexent Bio, Ted is leveraged his hybrid experience in oncotherapeutics and molecular diagnostics to develop the Confera™ DX system for therapy response monitoring. He has deep experience in both sectors, having built and led the original commercial team at Genomic Health that created and launched the Oncotype® DX product line in 2004. Before that, he led oncology marketing teams at Amgen and ALZA. He later built the commercial team at Crescendo Bioscience, now part of Myriad Genetics, where he launched the Vectra® DA system for disease management in rheumatology. Returning to therapeutics, he was Oncology/Hematology Business Unit Head at Jazz Pharma. He then served as CBO at Counsyl, an innovative NGS lab in reproductive genetics. More recently, he was the first CCO at Guardant Health. Ted is in a very small group that has successfully commercialized separate RNA, DNA & Proteomic tools for specialty medicine, unlocking widespread clinical adoption. Ted earned a BA in Economics from the University of Idaho, and an MBA from the University of Michigan. He also served as a pilot in the US Navy.